Zhao Yingdai, Zhang Hongzhe, Guo Shengnan, Wang Jinhuan, Yao Junjie, He Fan, Ying Xixiang
School of Pharmacy, Liaoning University of Traditional Chinese Medicine, Dalian, Liaoning, P.R. China.
Guangdong Provincial Hospital of Chinese Medicine, Guangdong Provincial Academy of Chinese Medical Sciences, Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, PR China.
Nat Prod Res. 2024 Jul 21:1-8. doi: 10.1080/14786419.2024.2381653.
Two new carbon skeleton compounds, identified as 2-(1-(3-hydroxy-2,2,6-trimethyl-6-vinyltetrahydro-2-pyran-3-yl)-2-methylpropoxy)-6-(hydroxymethyl)tetrahydro-2-pyran-3,4,5-triol named Olerapyran A (), and (E)-3-(6-acetyl-2-methyl-5-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2-pyran-2-yl)oxy)cyclooctylidene)butan-2-one named Oleraoctyl (), were first isolated from L., then their structures were determined using spectroscopic methods, including UHPLC-ESI-QTOF/MS, 1D and 2D NMR. In addition, the activities of Olerapyran A and Oleraoctyl inhibiting nitric oxide (NO) were studied.
两种新的碳骨架化合物,分别鉴定为2-(1-(3-羟基-2,2,6-三甲基-6-乙烯基四氢-2-吡喃-3-基)-2-甲基丙氧基)-6-(羟甲基)四氢-2-吡喃-3,4,5-三醇,命名为奥莱拉吡喃A(),以及(E)-3-(6-乙酰基-2-甲基-5-((3,4,5-三羟基-6-(羟甲基)四氢-2-吡喃-2-基)氧基)环辛叉基)丁-2-酮,命名为奥莱拉辛基(),首次从L.中分离得到,然后使用包括超高效液相色谱-电喷雾电离-四极杆飞行时间质谱、一维和二维核磁共振等光谱方法确定了它们的结构。此外,还研究了奥莱拉吡喃A和奥莱拉辛基抑制一氧化氮(NO)的活性。